(Editors' Note: This article covers a stock that is trading at less than $1 per share and/or has less than a $100 million market cap. Please be aware of the risks associated with these stocks.)
Writing anything positive about LipoScience (NASDAQ:LPDX) was a losing move in 2013, as the stock moved steadily down throughout the year. Making matters worse, it wasn't just a "the market doesn't get it" phenomenon as the company logged three straight quarters with revenue year-on-year revenue declines - something nobody wants to see from a company that is supposed to be in the early days of a major product launch.
I continue to believe there's still hope here, even if that hope has been...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|